Zoetis Inc. (ZTS) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$73.43

Open

$73.47

Day range

$72.93 – $73.89

Volume

4.6M

About Zoetis Inc.

Latest ZTS news

• Zoetis (ZTS) Shares Drop After Earnings Revision
  Yahoo Finance · Sep 8, 2026

  Zoetis Inc. (ZTS) experienced a notable decline in its stock price, dropping 2.22% to close at $76.09 following the release of its second-quarter earnings report. The company reported a profit of $691 million, but this fell short of analysts' expectations, prompting a revision of its earnings guidance for the remainder of the year. This disappointing performance has raised concerns among investors, particularly as the company faces weakening demand in the U.S. pet care market. The stock's decline comes at a time when Zoetis is already trading near its 52-week low, reflecting broader market apprehensions about its growth trajectory. Analysts are divided on the company's potential for recovery, with some suggesting that the current challenges in pet demand could persist, impacting future earnings. Additionally, the recent trimming of stakes by institutional investors and a transition in the CFO role have added to the uncertainty surrounding Zoetis. As the market digests these developments, investors will be closely monitoring the company's strategic responses and any potential shifts in consumer behavior in the pet care sector.

• Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
  Yahoo Finance · Aug 23, 2026

  Zoetis Inc. reported its latest earnings, revealing a mixed performance that highlights a divided business landscape amid declining consumer demand. While the company remains a leader in the animal health sector, the results indicate that its strong market position is not immune to broader economic pressures. The earnings report showed a slowdown in sales growth, prompting concerns about the sustainability of its current performance and the effectiveness of its strategic initiatives. Despite these challenges, Zoetis is banking on its robust pipeline of new products to reignite growth. Analysts are closely monitoring the company's research and development efforts, which could potentially lead to innovative treatments and vaccines that address emerging health issues in livestock and pets. The company currently trades at 12 times forward earnings with a dividend yield of approximately 3%, suggesting that investors may find value in its stock following a recent drawdown. Market implications of Zoetis's performance are significant, as investors weigh the potential for recovery against the backdrop of fluctuating consumer demand. The company's ability to execute on its pipeline and adapt to changing market conditions will be crucial in restoring investor confidence and driving future growth. As the animal health market continues to evolve, Zoetis's strategic decisions in the coming quarters will be pivotal in determining its trajectory.

• Zoetis (ZTS) Remains a Leader, So Why Was It Sold?
  Yahoo Finance · Aug 14, 2026

  Zoetis Inc. (ZTS), a leading global animal health company, has recently seen a notable decline in its stock price, prompting questions about the reasons behind this sell-off. Despite its strong market position and consistent financial performance, the stock has faced pressure from broader market dynamics and investor sentiment. Analysts point to a combination of factors, including macroeconomic concerns, rising interest rates, and potential headwinds in the agricultural sector, which could impact demand for animal health products. The sell-off may also reflect a shift in investor focus toward sectors perceived as more resilient in the face of economic uncertainty. As inflationary pressures continue and consumers tighten their spending, companies like Zoetis, which rely heavily on livestock and pet care markets, could experience slower growth. Additionally, competition in the animal health space is intensifying, with new entrants and innovative products challenging established players. Market analysts remain cautiously optimistic about Zoetis's long-term prospects, citing its robust product pipeline and commitment to research and development. However, the recent stock movement underscores the importance of monitoring external economic factors and industry trends that could influence investor confidence. As the market navigates these challenges, Zoetis's ability to adapt and maintain its leadership position will be critical in determining its future performance.

• Zoetis (ZTS) Looked Like a Winner. What Went Wrong?
  Yahoo Finance · Aug 10, 2026

  Zoetis Inc. (NYSE: ZTS), a leading player in the animal health sector, reported stagnant sales for the second quarter of 2026, with revenues holding steady at $2.47 billion compared to the previous year. This lack of growth has raised concerns among investors, particularly as the company revised its full-year revenue guidance downward to a midpoint of $9.22 billion, which is 5.4% lower than earlier projections. The disappointing earnings announcement led to a notable sell-off in Zoetis shares, which fell further in late trading sessions following the report. Market analysts had anticipated a more robust performance from Zoetis, especially given the overall positive outlook for the branded pharmaceuticals industry. The stagnation in sales raises questions about the company’s ability to capitalize on potential tailwinds in the sector, such as increased demand for animal health products. Investors are now closely monitoring how Zoetis plans to address these challenges and whether it can regain momentum in a competitive market. The stock's recent performance reflects a broader caution among investors regarding the company's growth trajectory and its ability to innovate in a rapidly evolving industry.

• Zoetis Target of Unusually High Options Trading (NYSE:ZTS)
  Options Market · Jul 20, 2026

  Zoetis Inc. (NYSE:ZTS) experienced a significant surge in options trading on Monday, with investors purchasing 8,095 call options, marking a 59% increase over the typical daily volume of 5,087. In a contrasting trend, the company also saw a remarkable spike in put options, with 11,543 contracts traded, representing a staggering 407% increase compared to the average of 2,278 put options. This unusual activity suggests a heightened interest in the stock, potentially driven by speculation or anticipation of upcoming news affecting the company. The surge in both call and put options could indicate a divergence in market sentiment regarding Zoetis. While the increased call volume may reflect bullish expectations among some investors, the substantial rise in put options suggests that others are hedging against potential declines or are pessimistic about the stock's near-term performance. Such mixed signals could lead to increased volatility in Zoetis shares, as traders react to the underlying factors influencing the stock. Market analysts will likely be monitoring Zoetis closely in the coming days to assess the implications of this unusual trading activity. Investors may want to consider the broader market conditions and any forthcoming earnings reports or announcements that could impact the company's performance. As options trading often serves as a barometer for investor sentiment, the current activity surrounding Zoetis could provide valuable insights into market expectations for the company.

• Zoetis to acquire VitalRADS, a provider of veterinary imaging services
  Seeking Alpha · Jul 14, 2026

  Zoetis Inc., a leading global animal health company, has announced its acquisition of VitalRADS, a provider of veterinary imaging services. This strategic move is expected to enhance Zoetis' portfolio by integrating advanced imaging technologies that can improve diagnostic capabilities for veterinarians. The financial terms of the deal have not been disclosed, but the acquisition aligns with Zoetis' ongoing commitment to expand its offerings in the veterinary market. Market analysts view this acquisition as a positive development for Zoetis, as it could lead to increased revenue streams and strengthen its competitive position in the growing veterinary services sector. The demand for advanced diagnostic tools in animal healthcare is on the rise, driven by a greater emphasis on pet health and wellness. By incorporating VitalRADS' imaging services, Zoetis may also enhance its relationships with veterinary professionals, potentially leading to increased sales of its pharmaceutical products. Investors are likely to monitor the integration process closely, as successful execution could yield significant long-term benefits for Zoetis. The acquisition may also signal a trend of consolidation in the veterinary services industry, as companies seek to leverage technology to improve service delivery and patient outcomes. Overall, this acquisition underscores Zoetis' proactive approach to innovation and market expansion in the evolving landscape of animal health.

• Confirmed screwworm case in Texas sends two biotech stocks higher
  CNBC · Jun 4, 2026

  A confirmed case of the New World screwworm in South Texas has sparked significant interest in the biotech sector, particularly among animal health companies. The U.S. Department of Agriculture reported that the infestation was detected in a three-week-old calf in La Pryor, marking the first occurrence of this flesh-eating parasite in the U.S. in decades. This development has led to a surge in options trading for Zoetis, a leading animal health company, as investors speculate on potential market winners in response to the outbreak. The implications for the cattle industry could be substantial, as the New World screwworm poses a serious threat to livestock health and productivity. Traders are betting that companies like Zoetis, which specializes in veterinary pharmaceuticals and vaccines, may see increased demand for their products aimed at controlling and preventing such infestations. The heightened interest in these stocks reflects a broader concern about the potential economic impact on cattle ranchers and the agricultural sector if the screwworm spreads further. While the immediate market reaction has been positive for these biotech stocks, analysts caution that it remains to be seen whether this is a short-term spike or the beginning of a more sustained trend. Investors will be closely monitoring the situation as authorities implement control measures and assess the risk of further outbreaks.

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen